Bill Commons

NY S 6074

in committee

Establishes the Sickle cell disease education and mapping program

New York · 2025-2026 Regular Session · upper

Quick answers

Did NY S 6074 pass?

Not yet. NY S 6074 is in committee as of 2026-01-07 and has not come to a final vote. Latest recorded action (2026-01-07): REFERRED TO HEALTH

What is NY S 6074 about?

Establishes the sickle cell disease education and mapping program to promote the screening and detection of sickle cell disease, educate the public regarding sickle cell disease, provide counseling and referral services and map locations of occurrence of sickle cell disease.

Who sponsors NY S 6074?

Kevin S. Parker is the primary sponsor of NY S 6074.

Description

Establishes the sickle cell disease education and mapping program to promote the screening and detection of sickle cell disease, educate the public regarding sickle cell disease, provide counseling and referral services and map locations of occurrence of sickle cell disease.

Introduced
—
Latest action
2026-01-07 — REFERRED TO HEALTH
Bill type
bill
Last updated
—

Sponsors

  • Kevin S. Parkerprimary

Committees

Not provided by source.

Action timeline

  1. 2025-03-05

    REFERRED TO HEALTH

    referral-committee

  2. 2026-01-07

    REFERRED TO HEALTH

    referral-committee

Versions

Documents

Votes

Not provided by source.

Related bills

  • Prior session: S 8923not in this corpus

Official source

Attribution

Data from openstates_bulk_csv, retrieved 2026-07-24T05:28:30.722574Z

Inspect retained evidence for changes recorded after evidence tracking began:

Session-wide evidence can include changes to other bills:

Use this data

Every field on this page is available from the free public API — no key or licence required. Fetch this bill as JSON: GET /api/v1/bills?jurisdiction=NY&identifier=S 6074. See the API docs or the MCP server for AI assistants.

Known limitations

  • Sponsor party and chamber affiliation are not yet captured by this API.
  • Committee referrals are not yet captured.

See the methodology page for data sources and limitations.